July - 2019

MECFA Blog

Tezacaftor, Ivacaftor Combination Generally Safe, Well Tolerated in Children With CF Under Age 12

Data from a phase 3 trial are supporting the use of tezacaftor in combination with ivacaftor for the treatment of cystic fibrosis (CF) in...

Different CFTR Potentiators Bind to Same Flexible Spot on Protein, Study Finds

Approved and investigative cystic fibrosis (CF) treatments known as CFTR potentiators work by binding to the same flexible protein spot —...

Eluforsen Improves CFTR Function in Cellular and Animal Models of CF, Study Says

Eluforsen, an investigational therapy for the treatment of cystic fibrosis (CF), improves the function of the cystic fibrosis...

Kalydeco’s Safety and Benefits Studied in CF Patients with Severe Lung Disease

Treatment with Kalydeco (ivacaftor) improved lung function, exercise capacity, and sweat chloride concentration in cystic fibrosis (CF)...

Specific Variables Improve Disease Severity Discrimination Among CF Transplant Candidates

The inclusion of Cystic Fibrosis Foundation Patient Registry variables in the lung allocation score (LAS) calculation allowed for...

Babies Treated with Synagis Show No Lasting Benefits in Lung Health as 7-Year-Olds, Real-world Study

Treating infants with cystic fibrosis (CF) with the antiviral therapy Synagis(palivizumab) does not improve long-term outcomes in lung...

Organoids grown in microfluidic device may help cf patients with diabetes

Scientists created human pancreas on a chip that allowed them to identify the possible cause of a frequent and deadly complication of...

Modified and More Rigorous Cleansing Procedure May Better Prepare CF Patients for Colonoscopy, Study

People with cystic fibrosis (CF) may require a modified and more rigorous cleansing procedure to prepare their bowels for a colonoscopy...

Combining Antibiotics, Researchers Deliver One-Two Punch Against P. aeruginosa

By combining two well-established antibiotics for the first time, a scientific team led by Case Western Reserve University School of...

AiCuris and Lysando Join Forces in the Fight Against Antimicrobial Resistance

Cooperation focused on the joint development and optimization of human anti-infective drug candidates against gram-negative and...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p